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To determine the spectrum of MEN1 muta-
























 gene mutations by
single-strand conformational polymorphism (SSCP)
and DNA sequence analysis of the coding region and





methods identified 4 different heterozygous mutations
in four families: two mutations are novel (mt 1539 delG
and mt 655 ims 11 bp) and two have been previously
observed (mt 735 del 46p and mt 1656 del C) all
resulting in a premature stop codon. In the remaining
two families, in whom no mutations or abnormal





 intragenic marker D11S4946 and codon 418
polymorphism in exon 9 revealed two large germline
deletions of the MEN1 gene. Southern blot and
tumour loss of heterozygosity analysis confirmed














polymorphic site D11S4946 to exon 9 (obliterating
the initiation codon), in the other family. Twenty-six





These results emphasize the import-
ance of the detection of MEN1 germline deletions in
patients who do not have mutations of the coding
region. Important clues indicating the presence of
such deletions may be obtained by segregation
studies using the intragenic polymorphisms D11S4946
and at codon 418. The detection of these mutations
will help in the genetic counselling of clinical manage-
ment of the MEN1 families in Portugal.
 
Multiple endocrine neoplasia type 1 (HUGO MEN1; MIM
131100; GenBank U93237) is an autosomal dominant disorder
characterized by the combined occurrence of tumours of the
parathyroid glands, pancreatic islet cells and anterior pituitary




, 1996). In addition, adrenal cortical
tumours, carcinoid tumours, facial angiofibromas, collagenomas,
lipomas and paragangliomas have also been described in patients


















, 1989; European Consortium on MEN1, 1997a)





, 1997; European Consortium on
MEN1, 1997b) that encode a novel 610 amino acid protein,





Functional studies of the MENIN protein, which does not have










, 1998), and interacts directly with the N-terminus of
the activating protein 1 (AP-1) transcription factor JunD, to





More than 300 germline and somatic mutations of the MEN1
gene have been identified to date. These mutations are distributed
throughout the coding region, suggesting that multiple domains
of the protein are responsible for its biological function. However,
approximately 19% of all the germline MEN1 mutations involve
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, 1998; Pannett & Thakker, 1999). Seventy-five
per cent of the MEN1 mutations cause truncation of MENIN
protein, probably resulting in loss of function (Pannett & Thakker,
1999). These data, and the observation that many tumours arising


















 gene suppresses tumori-





are consistent with the proposal that MEN1 is a tumour suppres-
sor gene. So far, no correlation between genotype and the clinical
phenotype has been established.




 gene mutations in the
Portuguese population, and to identify mutation-carriers, a
national consortium was established between the Portuguese
endocrinology groups. Six unrelated MEN1 families were










The diagnosis of MEN1 in the six families was based on the pres-
ence of tumours in two or more of the three main MEN1-related
tissues, i.e. parathyroid, anterior pituitary and pancreatic islet
cells tumours. Diagnosis of familial MEN1 required at least





, 1996). Venous blood samples were obtained from
20 symptomatic members (9 males and 11 females, age range
12–73 years) and 19 asymptomatic members (3 males and
16 females, age range 6–85 years) of the six MEN1 families.
Paraffin embedded tissues from 1 gastrinoma and 2 hyperplastic
parathyroid glands were also obtained from patient 17. Patients
gave their informed consent to participate in this study, and the
protocol was approved by the Ethics Committee of the Instituto
Português de Oncologia.
 






Genomic DNA from peripheral blood leucocytes and histological








 gene were sought for initially in the probands of the six
families by single-strand conformational polymorphism analysis














, 1998) primers and PCR conditions. The
DNA sequence of PCR products with abnormal SSCP bands was








, 1996). All the mutations or polymorphisms identified
were confirmed by at least two independent experiments. Family
members were examined for the mutations either by restriction-
enzyme analysis or by SSCP or by agarose-gel electrophoresis
of genomic PCR products obtained by the use of the appropriate
primers. Probands from families with negative SSCPs were
analysed further by direct sequencing of exons 2–10 of the MEN1
gene and of their corresponding 16 exon/intron boundaries








Four polymorphic microsatellite loci from chromosome 11q13,
located proximal (cen – PYGM, D11S449, D11S913 – qter) or




 gene, were used to screen
for LOH in a gastrinoma and in two hyperplastic parathyroid








, 1996). LOH was defined as visible absence of an allele or
a > 90% reduction in the signal for one allele in the tumour
compared with the matching blood DNA. Segregation of MEN1
with the above-described polymorphic loci was also investigated
in the families.
 






RNA was extracted from peripheral blood lymphocytes, using
TRIzol Reagent (Gibco BRL, Gaithersburg, USA) following the
manufacturer’s instructions. Complementary DNA (cDNA) was
then synthesized using random primers (Gibco BRL, Gaithers-
burg, USA) and SuperScript II reverse transcriptase (Gibco BRL,
Gaithersburg, USA) according to the protocols recommended by
the manufacturer. Primers were devised to amplify 4 overlapping
cDNA segments (nts 114–753, 633–1061, 1001–1474, 1428–
1972) covering the entire MEN1 coding region (exons 2 through
10). Primer sequences and reaction conditions are available





Fifteen micrograms of genomic DNA, from individuals of fam-
ilies with no detectable mutations and from 10 healthy controls,

















Biolabs, Beverly, USA) and Southern blot analysis using Hybond
N + nylon membranes (Amersham Pharmacia Biotech, Buck-




P-labelled probes corresponding to
GAPDH (human glyceraldehyde-3-phosphate dehydrogenase)








 (nts 152–753 and 1012–1474, covering exons 2 and 3 and




., 1996). Primer sequences and reaction conditions are available
upon request. Densitometric analysis of the band intensities was
performed using the ONE-Dscan software (Scanalytics, Division
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of CSPI, USA). The corrected intensities of the restriction frag-
ments detected with the MEN1 probe were obtained calculating
the ratio between the intensity of the fragment detected with the







Six unrelated Portuguese families were examined for MEN1
germline mutations. The clinical characteristics are summarized
in Table 1. The occurrence of tumours in the three major systems




 gene mutant carriers examined in this study was
17/26 (65%) for the parathyroids, 10/26 (38%) for the anterior





The analysis of SSCPs obtained from the study of the six probands
revealed four abnormal patterns of bands. DNA sequence
analysis of these four SSCP abnormalities revealed four MEN1
germline mutations in patients 1, 5, 11 and 14 (Table 1). These
mutations were heterozygous, and consisted of: two previously
described deletions (nt1656delC in exon 10 and nt735del4bp








, 1998) found in
patients 1 and 5, respectively; and two new mutations that
consisted of an 11-bp insertion in exon 3 (nt655ins11bp), which
leads to a frameshift that results in five missense amino acids
followed by a premature stop codon, found in patient 11 (Fig. 1);
and a deletion in exon 10 (nt1539delG), which leads to a
frameshift that results in 81 missense amino acids followed by
a premature stop codon, found in patient 14 (Table 1). All muta-
tions were verified by direct sequencing of both strands. The
11 bp insertion at codon 182, exon 3, was confirmed by agarose
gel electrophoresis (Fig. 1b). Furthermore, this mutation creates




I, and this facilitated
an independent confirmation of the insertion. The four base pair
deletion in exon 3, nt735 was also confirmed by gel electrophore-
sis, as it resulted in heteroduplex formation. The deletion of a G




I (CCC/GGG) and this was used to confirm the mutation.
In families 1–4, segregation studies, SSCP, restriction digest ana-
lysis or agarose gel electrophoresis of PCR products from other
family members confirmed that the mutations co-segregated with
the disease state. In total, 27 members were examined with these





In the remaining 15 members who were clinically and biochem-
ically unaffected, four were found to harbour MEN1 mutations
(age range 12–17 years) and the remaining 11 members had no
mutations. The young ages of the four mutant gene carriers is













In families 5 and 6, mutations were not detected by direct DNA




 gene and of their
corresponding 16 exon/intron boundaries. In these probands we
also searched for abnormal mRNA transcripts because our




 gene would not include the
branch sites, which are conserved intronic sequences known to
be functionally important to form the lariat-shaped structure in





mRNA, in both families, did not detect abnormalities. In order
to confirm that the disease gene was located on chromosome
11q13, we performed haplotype analysis and this demonstrated
co-segregation of PYGM, D11S449, D11S913 with MEN1 in
these families. However, in family 6 a deletion of the maternal
allele involving the intragenic locus D11S4946 was detected
(Fig. 2a). To assess further the extent of this deletion, we analysed
by SSCP and direct sequencing, the segregation of a commonly





confirmed the absence of the maternal polymorphic sequence
(GAT) in individual 25 from family 6 (Fig. 2b). Southern blot
analysis of individuals from family 6 and 10 healthy controls did
not reveal abnormal restriction fragment length polymorphisms
(RFLPs) (Table 2). However, the corrected intensities of the
restriction fragments in the three affected and two asymptomatic
individuals, previously suspected to be carriers (25 and 26),
were approximately 1 : 2 of that in the normal controls, thus




 gene. Taken together,
these findings indicate that the large germline deletion in








polymorphic site D11S4946 at least to exon 9 (Fig. 3). This
deletion is < 600 kb in size, because heterozygosity of the
sites D11S449 (~500 kb telomeric) and PYGM (~55 kb centro-
meric) is retained (European Consortium on MEN1, 1997a,
1997b).
In family 5, heterozygosity was retained for the D11S4946
locus (data not shown). An analysis of the exon 9 polymorphism,
by SSCP and direct DNA sequencing, revealed a deletion of the
maternal sequence (GAC) in patient 21 (Fig. 4). Southern blot













I (Fig. 3), revealed different RFLPs,
with 3·3 kb and 5·7 kb, respectively, in the affected individuals,
which were not present in 10 healthy controls (Fig. 5, Table 2).





, which covers exons 7–10 (Fig. 3), suggesting that these
exons are lost (Table 2). These findings are supported by the









































 gene mutations and associated phenotypes
Family Patient no. Pedigree Age*
Phenotype MEN1 germline mutation
Sex Parathyroid Anterior pituitary Enteropancreatic Other Exon Codon Mutation Predicted effect




 Ca** Macroaden 
(+ PRL, + GH)
Panc gastrinoma Lung carcinoid§ 10 516 nt 1656delC fs42aaX
2 D1 14 F – – – –
3 B1 40 M HPT – – –
4 D3 19 F HPT – – –
2 5 Index 20 M HPT Macroprolactinoma – – 3 209–210 nt 735del4bp fs13aaX
6 Si5 17 F – – – –




 PTH – – –
8 Mo5 43 F HPT Macroaden 
(+ PRL, + GH)
Malignant insulinoma§ –







10 S9 12 M – – – –




 3 182 nt 655ins11bp fs5aaX
12 S11 21 M HPT – – –
13 D11 15 F – – – –








 10 477 nt 1539delG fs81aaX
15 Fa14† 60 M – – Subtotal gastrectomy‡ Larynx carcinoma§
16 D14 26 F – Macroprolactinoma – –










18 Si17 32 F HPT – – –
19 Mo17 59 F HPT –¶ Hypergastrinaemia¶ –




21 S20† 48 M HPT (1 Ad§) Macroaden 
(nonproducing)§
Multiple gastric and 
duod gastrinomas§
Adrenal hyp
Panc endoc carcinoma 
(nonproducing)§










 (D11S4946) – exon 9]
23 Si22 51 F HPT (Hyp 4 glands§) Microaden 
(nonproducing)
Hypergastrinaemia Adrenomyelolipoma
24 Si22 41 F HPT (Hyp 4 glands§) Macroaden 
(nonproducing)§
Multiple glucagonomas 
(+ GLUC, + PP)§
–
25 D23 22 F – – – –
26 D23 27 F – – – –
 
*Age at genetic analysis; Ad, adenoma; Angiof, facial angiofibromas; B, brother of; D, daughter of; F, female; Fa, father of; fs, frameshift; GH, growth hormone; GLUC, glucagon; Hyp, hyperplasia; HPT, 
hyperparathyroidism; INS, insulin; M, male; Macroad, macroadenoma; Microad, microadenoma; Mo, mother of; Panc, pancreatic; PP, pancreatic polypeptide; PRL, prolactin; PTH, parathyroid hormone; S, son of; 
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Fig. 1 Detection of a mutation in exon 3 of the 
MEN1 gene in family 3. Below each symbol is the 
individual’s number according to Table 1. Agarose 
gel electrophoresis, SSCP and DNA sequence 
analysis of individuals 11, 12 and 13 revealed an 
11-bp insertion (insAAACACTACTA) at the 
second position of codon 182. This insertion is 
predicted to cause a frameshift that continues 
to codon 187, before a stop codon (TAG) is 
encountered (a). The 11 bp insertion could be 
visualized directly on a 3% agarose gel stained 
with ethidium bromide as the mutant (m) PCR 
product is 201 bp whereas the wild-type (WT) 
product is 190 bp. The mutant-gene carriers (11, 
12 and 13) were heterozygous, and individual I.2 
was homozygous for the wild-type sequence. N1, 
N2 and N3 are 3 unrelated normal individuals (b). 
Direct sequencing of exon 3 shows an 11-bp 
insertion in the mutant allele. The insertion point 
is indicated by an arrow, and the inserted bases 
(INS) are shown (c). Individuals are represented 
as male (squares), female (circles), unaffected 
(unblackened/unmarked symbols), affected 
with hyperparathyroidism (symbols with 
blackened upper-left quadrant), affected with 
enteropancreatic tumour(s) (symbols with 
blackened lower-left quadrant), affected with 
anterior pituitary tumour(s) (symbols with 
blackened upper-right quadrant), affected with 
other MEN1 lesions (symbols with blackened 
lower-right quadrant), and unaffected mutant-gene 
carriers (symbols containing a black dot).
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I did not reveal abnormal MEN1 RFLPs (Table 2). These














 gene (Fig. 3). In order to refine the limits of this
deletion, mapping studies, using MEN1 exon specific PCR
primers, of a gastrinoma and two parathyroid hyperplastic glands
from patient 17 (family 5), which showed loss of heterozygosity
involving the wild-type allele in all 11q13 studied loci (data not
shown), were undertaken. This revealed the presence of PCR
products from exons 2–6 but an absence of PCR products from
exons 7–10. These data from the MEN1 tumours indicate that
the mutated allele lacks the region containing exons 7–10 and




 untranslated region (Fig. 3); thus the germline




 gene is transcribed




., 1998), and as
heterozygosity at PYGM locus, which is ~55 kb away, is retained,
this deletion is likely to be < 55 kb in size.
In total, 12 members from family 5 and 6, with no mutations
detected by PCR-based sequencing analysis, were examined with
these alternative methods. All of the eight affected members had




 gene. In the remaining four
members, who were clinically and biochemically normal, two




 gene deletions. The ages of these two
mutant gene carriers were 22 and 27 years, and this is consistent

















Our study of six Portuguese kindreds with MEN1 has identified
six mutations (Table 1), and four of these represent novel abnor-
malities. These four new mutations consist of two large deletions,
one 11 bp insertion (nt655ins11bp), and a single base pair deletion
(nt1539delG). The two other mutations that consisted of a
4-bp (nt735del4bp) and a 1-bp (nt1656delC) deletion have been









, 1998). Our finding of the two large deletions
is of significance as it is important to realize that such deletions
will remain undetectable by the usual methods that are used to
search for mutations, e.g. SSCP, direct DNA sequence, and
Fig. 2 Detection of a large germline deletion of the 
MEN1 gene in family 6. Below each symbol is the 
individual’s number according to Table 1. Segregation 
studies, with the 5′ intragenic locus D11S4946, 
revealed the absence of the maternal allele in patient 
25 from family 6 (a). Segregation studies, performed 
by SSCP, of exon 9 polymorphism D418D 
(GAC→GAT), revealed also the absence of the 
maternal polymorphic sequence (GAT) in individual 
25, which is represented by the symbol 0 (b). Codon 
418 and D11S4946 locus were probably also absent 
in individual 26, the sister of the former, as 
segregation studies with MEN1 polymorphic flanking 
markers showed that she received the same maternal 
chromosome (data not shown). Hemizygosity for 
these loci was also found in the other affected 
individuals. N1, N2 and N3, are 3 unrelated normal 
individuals. The symbols for individuals are as 
indicated in Fig. 1.




Probe α Probe β
F5 F6 N F5 F6 N
KpnI 3·7 3·7 3·7 5·0 5·0 5·0
SacI 3·7 3·7 3·7 1·0 1·0 1·0
8·6 8·6 8·6 9·1 9·1 9·1
3·3
SacII* 7·3 7·3 7·3 7·3 7·3 7·3
0·4 0·4 0·4 0·4 0·4 0·4
SmaI 6·1 6·1 6·1 6·1 6·1 6·1
5·7
F, mutant MENI gene carriers from family; N, normal control 
individuals; *in this Southern blot probes α and β were used together.
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RT-PCR analysis. Moreover, by using such methods it has
been established that in 6% to 14% of the MEN1 families
MEN1 mutations will not be detected (Agarwal et al., 1997;
Chandrasekharappa et al., 1997; Bassett et al., 1998; Giraud et al.,
1998). Indeed, a sole reliance on these methods in our small series
of six families would have resulted in a failure to detect abnor-
malities of the coding region in 33% of the families. It has been
suggested that such MEN1 families may harbour mutations in
the regulatory or untranslated regions, or that may have hyper-
methylation of the GC-rich sequences of the 5′ region (Agarwal
et al., 1997; Bassett et al., 1998; Giraud et al., 1998). In addition,
such MEN1 families may have germline deletions as illustrated
by our studies (Table 1, Fig. 3) of families 5 (Fig. 4) and 6
(Fig. 2). In detecting these germline mutations, we obtained
important clues by examining the polymorphisms at codon 418
in exon 9, and by using microsatellite polymorphisms. Further-
more, Southern blot, and the analysis of tumours which had loss
of heterozygosity involving the wild-type allele and which there-
fore facilitated the detection of the mutant allele, helped to pro-
vide a confirmation of the germline deletions. The exact size of
these germline deletions is difficult to establish, but our studies
indicate that the deletion in family 5 may range between 3 and
55 kb, and that in family 6 may range from 6 to 600 kb. Such
germline deletions, which have been reported previously in only
two other families (Kishi et al., 1998; Bergman et al., 2000), are
likely to be more common than suspected hitherto, particularly
as they may have been missed by the usual methods of mutational
analysis. In regard to this, the careful examination of the codon
418 polymorphism, the use of microsatellite polymorphisms,
and the utilization of MEN1 RFLPs as illustrated by our results
will help to identify these germline deletions. The molecular
Fig. 4 Detection of a large germline deletion of the MEN1 gene in 
family 5. Below each symbol is the individual’s number according 
to Table 1. Segregation studies, performed by SSCP, of exon 9 
polymorphism D418D (GAC→GAT), showed a deletion of the maternal 
sequence (GAC) in patient 21, which is represented by the symbol 
0. Hemizygosity for this locus was also found in the other affected 
individuals. Individual III.2 is not a carrier of the mutated allele, as 
segregation studies with D11S4946 and MEN1 polymorphic flanking 
markers, and also Southern blot analysis, showed that she received the 
wild-type maternal chromosome (data not shown). N1, N2 and N3, are 
3 unrelated normal individuals. The symbols for individuals are as 









Fig. 3 Large germline deletions in families 5 and 6. 
Positions in the MEN1 gene of the sequences 
recognized by the restriction enzymes used in the 
Southern blot analysis, and MEN1 exonic sequences 
detected by probes α and β, are shown. In family 5, 
the deletion starts somewhere after exon 6 and extends 
in the 3′ untranslated region. In family 6, the deletion 
spans the 5′ polymorphic site D11S4946 and extends 
at least to exon 9.
Fig. 5 MEN1 specific RFLPs detected by Southern blot analysis of 
DNA from an affected individual from family 5. The approximate sizes 
of the RFLPs were calculated using a standard curve derived from the 
molecular size marker Lambda DNA-HindIII Digest. Probe α, which 
spans exons 2–3, detected a 3·3-kb SacI RFLP and a 5·7-kb SmaI RFLP 
(indicated by an arrow) in the affected individual (Pt), but not in the 
unaffected control (C) (Table 2). These results confirm that this patient 
carries a large germline deletion. Identical results were obtained with the 
other affected individuals from this family.
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mechanisms that lead to these germline deletions remain to be
elucidated, but it is important to note that the patients and families
with these large germline deletions did not have more severe
phenotypes when compared to those with smaller deletions or
point mutations (Table 1). The molecular mechanisms causing
the smaller deletions are likely to be associated with flanking
DNA sequence repeats, which can give rise to a slipped-mispairing
at the replication fork, during replication, followed by nucleotide
excision as has been reported for the nt1656delC and nt735del4bp
mutations (Krawczak & Cooper, 1991; Bassett et al., 1998). The
same mechanism may explain the deletion of one G at codon 477,
detected in family 4. The nucleotide sequence flanking codon 477
is GC-rich, which is also known to correlate with a high deletion
frequency (Krawczak & Cooper, 1991), probably as a result of
the increased stabilization of deletion intermediates facilitating
slipped-mispairing. Indeed, it is of interest to note that an inser-
tion of one G has also been reported (Poncin et al., 1999) at this
precise site. Furthermore, the size and position of insertions are
reported (Cooper & Krawczak, 1991) to be non-random, and
highly dependent upon the surrounding DNA sequence, as in the
deletional mechanisms of mutagenesis. This is well illustrated by
the 11 bp insertion in exon 3, found in family 3 (Table 1), in
which nine of the 11 bp inserted in the mutated DNA sequence
(lower-case letters), if read in the antisense direction, are com-
plementary to a neighbouring nucleotide sequence, as follows:
5′ ... ATGCaaacactactaCTGGGTAGTGTTTGGGCCCAATG ... 3′.
Interestingly, the finding of six different mutations in these
Portuguese families confirms their unrelatedness and the absence
of a founder effect in the Portuguese population. Furthermore,
the younger ages of the asymptomatic, biochemically normal
mutant gene carriers confirms the age-related penetrance of this
disorder, and our results will help in the genetic counselling and
management of these patients.
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